[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-370237-105":59,"doc-detail-370237-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","advances-in-pyrazolo15-apyrimidines-synthesis-and-their-role-as-protein-kinase-inhibitors-in-cancer-treatment","Advances in pyrazolo[1,5-a]pyrimidines - synthesis and their role as protein kinase inhibitors in cancer treatment","","Pyrazolo[1,5-a]pyrimidines are highlighted as a heterocyclic scaffold with strong protein kinase inhibitor (PKI) activity for targeted cancer therapy. The review surveys recent synthetic progress, including cyclization, condensation, three-component reactions, microwave methods, green chemistry, and diversification via palladium-catalyzed cross-coupling and click chemistry. It links structure–activity relationships to pharmacological performance and summarizes evaluations of kinase selectivity, cytotoxicity, and antiproliferative effects across EGFR, B-Raf, MEK and other kinases. Remaining challenges include resistance, off-target effects, and toxicity, guiding future optimization of selectivity and bioavailability.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/advances-in-pyrazolo15-apyrimidines-synthesis-and-their-role-as-protein-kinase-inhibitors-in-cancer-treatment/370237/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/advances-in-pyrazolo15-apyrimidines-synthesis-and-their-role-as-protein-kinase-inhibitors-in-cancer-treatment/370237.png","ImageObject",300,407,{"name":92,"@type":93},"Eliana","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What makes pyrazolo[1,5-a]pyrimidines important for cancer therapy?","Question",{"text":112,"@type":113},"They are heterocyclic compounds with potent protein kinase inhibitor activity, which helps target disrupted kinase signaling pathways that support cancer cell survival and growth.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which kinase targets and cancer types does the review emphasize?",{"text":117,"@type":113},"The review discusses inhibition of kinases such as CK2, EGFR, B-Raf, MEK, PDE4, BCL6, DRAK1, CDK1/2, and Pim-1. EGFR-targeting derivatives are described as promising for non-small cell lung cancer (NSCLC), while B-Raf and MEK relevance is noted for melanoma.",{"name":119,"@type":110,"acceptedAnswer":120},"What synthesis strategies are covered for building these compounds?",{"text":121,"@type":113},"The review covers cyclization, condensation, three-component reactions, microwave-assisted methods, and green chemistry approaches, including palladium-catalyzed cross-coupling and click chemistry to introduce diverse functional groups.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},370237,1790804539,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":39,"preview_urls":146},4398048949847,"https://ap-avatar.wpscdn.com/avatar/400002536579ef2da7f?_k=1778318612642679267","RSC Advances  \nREVIEW  \nCite this: RSC Adv., 2025, 15, 3756  \nReceived 22nd October 2024 Accepted 30th December 2024 DOI: 10.1039/d4ra07556k  \n[rsc.li/rsc-advances](rsc.li/rsc-advances)  \nAdvances in pyrazolo[1,5-a]pyrimidines: synthesis and their role as protein kinase inhibitors in cancer treatment  \nTerungwa H. Iorkula,*a Osasere Jude-Kelly Osayawe,a Daniel A. Odogwu,a Latifat Oluwatobi Ganiyu,a Emmanuel Faderin, b Raymond Femi Awoyemi,c Busayo Odunayo Akodu,b Ikhazuagbe Hilary Iﬁjen, *d  \nOmowunmi Rebecca Aworinde,e Peter Agyemange and Odo Lovelyn Onyinyechif  \nPyrazolo[1,5-a]pyrimidines are a notable class of heterocyclic compounds with potent protein kinase inhibitor (PKI) activity, playing a critical role in targeted cancer therapy. Protein kinases, key regulators in cellular signalling, are frequently disrupted in cancers, making them important targets for small-molecule inhibitors. This review explores recent advances in pyrazolo[1,5-a]pyrimidine synthesis and their application as PKIs, with emphasis on inhibiting kinases such as CK2, EGFR, B-Raf, MEK, PDE4, BCL6, DRAK1, CDK1 and CDK2, Pim-1, among others. Several synthetic strategies have been developed for theeﬃcient synthesis of pyrazolo[1,5-a]pyrimidines, including cyclization, condensation, three-component reactions, microwave-assisted methods, and green chemistry approaches. Palladium-catalyzed crosscoupling and click chemistry have enabled the introduction of diverse functional groups, enhancing the biological activity and structural diversity of these compounds. Structure–activity relationship (SAR) studies highlight the inﬂuence of substituent patterns on their pharmacological properties. Pyrazolo[1,5-a]pyrimidines act as ATP-competitive and allosteric inhibitors of protein kinases, with EGFR-targeting derivatives showing promise in non-small cell lung cancer (NSCLC) treatment. Their inhibitory eﬀects on B-Raf and MEK kinases are particularly relevant in melanoma. Biological evaluations, including in vitro and in vivo studies, have demonstrated their cytotoxicity, kinase selectivity, and antiproliferative eﬀects. Despite these advances, challenges such as drug resistance, oﬀ-target eﬀects, and toxicity persist. Future research will focus on optimizing synthetic approaches, improving drug selectivity, and enhancing bioavailability to increase clinical eﬃcacy.  \n1 Introduction  \n1.1 Background on protein kinase inhibitors (PKIs) in cancer treatment  \nCancer remains one of the leading causes of mortality worldwide, with an estimated 10 million deaths in 2020 alone. The complex nature of cancer, characterized by uncontrolled cell proliferation, invasion, and metastasis, presents signi􀀁cant challenges in developing eﬀective treatments.1–5 Among the various therapeutic strategies, targeted therapy has emerged as  \naDepartment of Chemistry and Biochemistry, Brigham Young University, Provo, Utah, USA. E-mail: [terungwa@chem.byu.edu](terungwa@chem.byu.edu)  \nbDepartment of Pharmaceutical Sciences, Southern Illinois University, 1Harirpin Dr, Edwardsville, IL 62026, USA  \ncDepartment of Chemistry, Mississippi State University, MS 39762, USA dDepartment of Research Outreach, Rubber Research Institute of Nigeria, Benini City,  \nNigeria. E-mail: [larylans4u@yahoo.com](larylans4u@yahoo.com)  \neDepartment of Chemistry, Michigan Technological University, 1400 Townsend Dr, Houghton, MI 49931, USA  \nfFaculty of Pharmaceutical Sciences, University of Nigeria, Nsukka, Nigeria  \na highly promising approach, focusing on the selective inhibition of molecular pathways crucial for cancer cell survival and growth. Protein kinase inhibitors (PKIs) have become central to this strategy, oﬀering a mechanism to block aberrant signaling pathways that drive oncogenesis.6–9  \nProtein kinases are enzymes that regulate a wide array of cellular processes, including cell growth, diﬀerentiation, apoptosis, and metabolism, by transferring a phosphate group from ATP to speci􀀁c substrates. Disruption ","cbCaijb3FdezS1Op","https://ap.wps.com/l/cbCaijb3FdezS1Op","pdf",6300303,73,"English","# Introduction\n## Background on protein kinase inhibitors (PKIs) in cancer treatment","[{\"question\":\"What makes pyrazolo[1,5-a]pyrimidines important for cancer therapy?\",\"answer\":\"They are heterocyclic compounds with potent protein kinase inhibitor activity, which helps target disrupted kinase signaling pathways that support cancer cell survival and growth.\"},{\"question\":\"Which kinase targets and cancer types does the review emphasize?\",\"answer\":\"The review discusses inhibition of kinases such as CK2, EGFR, B-Raf, MEK, PDE4, BCL6, DRAK1, CDK1/2, and Pim-1. EGFR-targeting derivatives are described as promising for non-small cell lung cancer (NSCLC), while B-Raf and MEK relevance is noted for melanoma.\"},{\"question\":\"What synthesis strategies are covered for building these compounds?\",\"answer\":\"The review covers cyclization, condensation, three-component reactions, microwave-assisted methods, and green chemistry approaches, including palladium-catalyzed cross-coupling and click chemistry to introduce diverse functional groups.\"}]","Advances in pyrazolo[1,5-a]pyrimidines - synthesis and their role as protein kinase inhibitors in cancer treatment | PDF",1790187569,184,[147,151,155,159,163,167,171,175],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dca2fb29fea69ad74baad3402375cda9.webp",983,1287,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c8c4ebac0aedd1c5ddf0523fbb4de790.webp",982,1286,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1b5c16ca1e3c41b2580f180deec28740.webp",981,1284,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e080b4ca4f38e3fea6e22e0ebfeea810.webp",980,1283,{"page_no":24,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/62bdc9401efc47dd2a518ad010df2d0d.webp",979,1282,{"page_no":29,"url":168,"width":169,"height":170},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2a0b08a1829ead523b934d7d5801ab51.webp",978,1280,{"page_no":34,"url":172,"width":173,"height":174},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4c88630607988817f765d70752258a49.webp",977,1279,{"page_no":39,"url":176,"width":177,"height":178},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5c2f3ab4ff6a1a76c14ff5f532287d2a.webp",976,1278]